finanzen.net

Pain Therapeutics

Seite 2 von 2
neuester Beitrag: 28.03.19 16:34
eröffnet am: 09.01.18 17:56 von: Kurios1 Anzahl Beiträge: 32
neuester Beitrag: 28.03.19 16:34 von: Vassago Leser gesamt: 4536
davon Heute: 2
bewertet mit 0 Sternen

Seite: 1 |
 

05.10.18 09:21
1

871 Postings, 3134 Tage mehrmeerNews

werden auch bei I-Hub im Breakout Board angezeigt.Momentan auf Platz 4.Könnte helfen,die Amis stehen
auf Low Floater.-
https://investorshub.advfn.com/boards/breakoutboards.aspx  

05.10.18 09:22

1384 Postings, 826 Tage FrozenfrogHoffen wir

Mal. Das gestern war schon krass. Nur weil man mehr erwartet hat. Tsts  

24.12.18 17:25

4500 Postings, 913 Tage VassagoPTIE 0,80$

MK 14 Mio. $ < Cash 20 Mio. $  

26.02.19 13:03

17036 Postings, 3536 Tage Balu4u...

26.03.19 10:59

4500 Postings, 913 Tage VassagoPTIE 1,14$

Operating Highlights for 2018 and Forecast for 2019--

  • Historically, our lead drug candidate had been REMOXY, which is the trade name for an abuse-deterrent, extended-release form of oxycodone to treat severe chronic pain. The U.S. Food and Drug Administration (FDA) has previously found REMOXY to be an effective analgesic drug for the treatment of severe chronic pain. However, FDA has not approved REMOXY on the basis that additional demonstrations of its abuse deterrent properties are needed, a matter of dispute between us and FDA.


  •    On March 20, 2019, we provided Durect Corporation with written notice of termination of a Development and License Agreement (DLA). Termination of the DLA effectively ends our clinical development of REMOXY.
  • In October 2018, we announced a strategic reorganization to align Company resources on advancing our programs in neurodegenerative diseases, such as Alzheimer?s disease.
       
      --- In December 2018, we announced the initiation of a Phase II study to evaluate PTI-125 in patients with Alzheimer?s disease. This clinical study is supported by a research grant award from the National Institute on Aging of the NIH, the primary Federal agency supporting innovative new research in Alzheimer?s disease.

  • In 2019, we expect to rebrand the Company around neurodegeneration. Our rebranding plans include a new company name, logo, ticker symbol, website, as well as a comprehensive strategy to bolster media outreach and an active approach to engage with potential new shareholders.

http://investor.paintrials.com/news-releases/...results-and-corporate

 

28.03.19 16:34

4500 Postings, 913 Tage VassagoNamensänderung

Seite: 1 |
 
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Aramco (Saudi-Aramco)A2PVHD
Deutsche Bank AG514000
Daimler AG710000
NEL ASAA0B733
EVOTEC SE566480
Infineon AG623100
CommerzbankCBK100
Microsoft Corp.870747
Apple Inc.865985
Amazon906866
Varta AGA0TGJ5
BASFBASF11
Ballard Power Inc.A0RENB
Deutsche Telekom AG555750